Meeting
2017 ASCO Annual Meeting
Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial.
Authors
Vasiliki Pelekanou
Yale School of Medicine, New Haven, CT
Vasiliki Pelekanou , William E. Barlow , Marie-Kristin von Wahlde , Brad Wasserman , Ying-Chun Lo , Daniel F. Hayes , Gabriel N. Hortobagyi , Julie Gralow , Debu Tripathy , Robert B. Livingston , Peggy Porter , Zeina A. Nahleh , David L. Rimm , Lajos Pusztai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT00856492
Citation
J Clin Oncol 35, 2017 (suppl; abstr 519)
DOI
10.1200/JCO.2017.35.15_suppl.519
Abstract #
519
Poster Bd #
119
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.
First Author: Xiaotong Li
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2022 ASCO Annual Meeting
Clinical outcomes and immune markers by race in a phase I/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC.
First Author: Julia Foldi
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji